# Antiphospholipid Syndrome

Antiphospholipid syndrome requires a thrombotic or pregnancy morbidity phenotype plus persistent antiphospholipid antibodies. Management hinges on event type, antibody-risk profile, pregnancy status, and selection of warfarin rather than direct oral anticoagulation for arterial or triple-positive disease.

**Clinical question:** How should clinicians confirm antiphospholipid syndrome and select thrombosis prevention or anticoagulation by clinical phenotype and antibody profile?

Updated: 2026-08-24T18:21:49.279400+00:00

## What matters in practice
- Diagnose APS only when a qualifying thrombotic or pregnancy morbidity phenotype coexists with at least one persistently positive antiphospholipid antibody measured at least 12 weeks apart.[15][16]
- Order lupus anticoagulant functional testing plus anticardiolipin and anti-beta-2-glycoprotein I IgG/IgM immunoassays; repeat a first positive lupus anticoagulant test after 12 weeks.[12][13]
- For thrombotic APS, vitamin K antagonist therapy, usually warfarin, is the long-term standard; avoid DOACs in arterial APS and triple-positive profiles.[21][24]
- After arterial thrombosis, accepted warfarin strategies are INR 3.0-4.0 or INR 2.0-3.0 plus low-dose aspirin; balance recurrent thrombosis risk against bleeding risk.[21][22]
- In obstetric APS, low-dose aspirin plus heparin is the conventional pregnancy strategy.[21]
- Multiorgan thrombosis developing concurrently or within 1 week should trigger urgent evaluation for catastrophic APS, particularly when small-vessel occlusion and antiphospholipid antibodies are present.[18]

## Confirm APS before assigning lifelong anticoagulation

Separate transient antibody positivity from a persistent, clinically meaningful APS phenotype.

Establish APS when at least one clinical criterion coexists with at least one persistently positive antiphospholipid antibody. Qualifying clinical phenotypes include arterial, venous, or microvascular thrombosis and pregnancy morbidity; laboratory persistence requires repeat positivity at a minimum interval of 12 weeks.[12][15][16]

Order all three laboratory domains rather than relying on a single assay: phospholipid-dependent coagulation testing for lupus anticoagulant (LA), anticardiolipin antibody immunoassays, and anti-beta-2-glycoprotein I antibody immunoassays. LA testing is the most technically complex component and can be confounded by anticoagulant therapy or factor deficiency patterns in mixing studies.[12]

Treat a first positive LA result as provisional. Repeat LA testing after 12 weeks, and apply the same persistence principle to other antiphospholipid antibody results before labeling APS outside an immediately life-threatening thrombotic presentation.[12][13][15]
- A high-risk antibody profile includes LA, double or triple antibody positivity, or persistently high antibody titers.[6]
- Do not equate isolated antibody positivity with APS: an asymptomatic individual requires risk assessment, not a thrombotic APS diagnosis.[6][15]

*Clinical and laboratory elements that determine whether APS is established.[12][15][16]*

| Decision element | Actionable finding | Next action |
| --- | --- | --- |
| Clinical phenotype | Arterial, venous, or microvascular thrombosis; or qualifying pregnancy morbidity.[12][15] | Proceed with complete antiphospholipid antibody testing and assess alternative causes of the event. |
| LA testing | Positive phospholipid-dependent coagulation assay; first positivity requires repeat testing after 12 weeks.[12] | Interpret with the laboratory when concurrent anticoagulation or an abnormal mixing study may affect results.[12] |
| Solid-phase antibodies | Anticardiolipin and anti-beta-2-glycoprotein I IgG/IgM positivity.[12] | Repeat after at least 12 weeks to document persistence.[13][15] |
| Risk profile | LA, double/triple positivity, or persistently high titers.[6] | Use this profile to guide primary prevention discussions and avoid DOACs in high-risk thrombotic APS.[6][21][24] |

## Identify catastrophic APS and treat the acute event as thrombosis

Rapidly progressive multiorgan ischemia requires a different level of urgency than isolated thrombosis.

Suspect catastrophic APS (CAPS) when thromboses affect three or more organ systems simultaneously or within less than 1 week, particularly with histopathologic small-vessel occlusion and antiphospholipid antibody positivity. Thrombocytopenia may accompany CAPS and can resemble heparin-induced thrombocytopenia or disseminated intravascular coagulation.[18]

For suspected CAPS, obtain urgent imaging directed by organ ischemia, document thrombosis across involved vascular beds, and seek tissue confirmation of small-vessel occlusion when a safely accessible involved site exists. Coordinate hematology, rheumatology, critical care, and the relevant organ specialty while treating active thrombosis and evaluating competing diagnoses.[18]

Pregnancy is a recognized CAPS-associated setting: 8% of 500 CAPS Registry cases occurred in association with pregnancy. Escalate immediately when a pregnant or postpartum patient has concurrent thrombosis, thrombocytopenia, organ dysfunction, or rapidly evolving ischemic symptoms.[22]
- Do not delay acute thrombosis management solely to await the 12-week confirmatory antibody interval when the patient has an objectively documented thrombotic event and a clinically compatible APS presentation.[12][15]
- In APS with thrombocytopenia, recognize that warfarin requires caution because of its long half-life; anticoagulation intensity and agent selection require individualized bleeding-risk assessment.[22]

## Choose long-term anticoagulation by venous versus arterial APS

Warfarin is first-line for thrombotic APS; arterial events and triple positivity make DOAC use particularly unfavorable.

For thrombotic APS, use a vitamin K antagonist (VKA), preferably warfarin, as long-term secondary prevention. Current evidence-based guidance supports lifelong VKA therapy in thrombotic APS, with low-molecular-weight heparin or unfractionated heparin used in selected situations.[21][22]

For prior arterial thrombosis, do not use low-dose aspirin alone when APS is definite; VKA therapy is recommended over aspirin monotherapy.[2] Anticoagulation intensity remains clinically consequential: available strategies include warfarin with target INR 3.0-4.0 or warfarin with INR 2.0-3.0 plus low-dose aspirin. Select between them according to recurrent arterial thrombosis risk, prior bleeding, thrombocytopenia, and feasibility of stable INR monitoring.[21][22]

For recurrent thrombosis during warfarin therapy, first determine whether recurrence occurred at therapeutic anticoagulation intensity. If recurrence occurs on standard-intensity warfarin, options include adding low-dose aspirin, increasing the target INR to 3.0-4.0, or changing to LMWH.[22]

Avoid DOACs in high-risk APS, especially triple-positive patients and those with previous arterial events. A randomized trial in triple-positive APS was stopped early because thromboembolic events, predominantly arterial events, were more frequent with rivaroxaban than warfarin.[2][21] Some guidance allows carefully selected patients with low-risk venous APS to remain on or consider a DOAC when warfarin is not feasible, but evidence is limited and this approach does not apply to arterial APS or triple positivity.[21][24]
- Use INR 2.0-3.0 or 3.0-4.0 as VKA targets according to phenotype and bleeding versus recurrence tradeoffs.[22]
- If lupus anticoagulant makes the INR potentially unrepresentative of anticoagulation intensity, involve the anticoagulation laboratory or hematology service in monitoring strategy selection.[22]
- Review concurrent low-dose aspirin carefully, because its role after arterial APS is an adjunct to moderate-intensity warfarin rather than a substitute for VKA therapy.[2][21][22]

*Secondary thrombosis prevention choices in APS.[2][21][22][24]*

| Clinical pattern | Preferred long-term strategy | Avoid or escalate |
| --- | --- | --- |
| Thrombotic APS | VKA, preferably warfarin, for lifelong secondary prevention.[21][22] | Assess INR reliability when LA may interfere with measurement.[22] |
| First arterial thrombosis with definite APS | VKA rather than low-dose aspirin alone.[2] | Consider INR 3.0-4.0 or INR 2.0-3.0 plus low-dose aspirin based on bleeding and recurrence risk.[21][22] |
| Recurrent thrombosis on standard-intensity warfarin | Add low-dose aspirin, increase target INR to 3.0-4.0, or transition to LMWH.[22] | Confirm recurrence occurred while therapeutic before intensifying treatment. |
| Triple-positive APS or prior arterial APS | Warfarin/VKA.[21][24] | Avoid DOACs; rivaroxaban had excess thromboembolic events in triple-positive APS.[2] |
| Low-risk venous APS when warfarin is not feasible | Warfarin remains preferred; selected patients may be considered for DOAC therapy in limited circumstances.[21][24] | Do not extrapolate this exception to arterial APS or triple-positive profiles.[21][24] |

## Manage asymptomatic high-risk antibody profiles differently from thrombotic APS

Persistent antibodies without thrombosis do not establish APS but may justify primary prevention in high-risk profiles.

For an asymptomatic individual with a persistent high-risk antiphospholipid antibody profile, low-dose aspirin is recommended for primary prophylaxis in the EULAR framework. High-risk status includes LA, double or triple positivity, or persistently high titers.[6]

The estimated thrombosis incidence in high-risk antibody profiles may be as high as 5% per person-year, supporting a distinct prevention discussion from that used for isolated low-risk antibody positivity.[6] Confirm persistence before committing to prophylaxis, and distinguish primary prevention from the lifelong VKA strategy used after documented thrombotic APS.[6][21]
- Use low-dose aspirin for primary prophylaxis only in the persistent high-risk antibody setting described above; aspirin does not replace VKA treatment after arterial APS.[2][6]
- Reassess antibody profile when initial results are new, because persistence at 12 weeks changes risk categorization and diagnostic confidence.[12][15]

## Use antibody testing and pregnancy-directed antithrombotic therapy

Pregnancy morbidity should prompt APS testing and a treatment plan distinct from nonpregnant thrombotic APS.

Evaluate pregnancy morbidity for APS with LA, anticardiolipin, and anti-beta-2-glycoprotein I testing; one or more morphologically normal fetal losses after the 10th gestational week qualifies as an adverse pregnancy outcome in APS criteria.[12][14] When testing follows pregnancy loss, repeat a positive LA or anticardiolipin result after a further 12 weeks to establish persistence.[14]

LA and anticardiolipin antibodies are associated with recurrent fetal loss. In meta-analysis, LA was associated with late recurrent fetal loss (odds ratio 7.79, 95% CI 2.30-26.45), and IgM anticardiolipin antibody with late recurrent fetal loss (odds ratio 5.61, 95% CI 1.26-25.03).[14]

For obstetric APS, use combination low-dose aspirin plus heparin as the conventional treatment strategy.[21] Do not substitute a DOAC for pregnancy-directed heparin-based therapy; DOAC evidence and guideline exceptions discussed for selected low-risk venous APS do not establish a role in obstetric APS.[21][24]
- Document whether pregnancy morbidity occurred with vascular thrombosis, because thrombotic APS has an independent indication for long-term VKA-based secondary prevention outside pregnancy.[21][22]
- Escalate urgently for pregnancy-associated multiorgan thrombosis or thrombocytopenia because CAPS has been reported in association with pregnancy.[18][22]

## References
1. rdf:RDF — casereports.bmj.com — https://casereports.bmj.com/rss/recent.xml
2. EULAR recommendations for the management ... — ard.bmj.com — https://ard.bmj.com/content/78/10/1296
3. 2024 Guideline for the Primary Prevention of Stroke — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/STR.0000000000000475
4. Secondary prevention with antiplatelet medications in patients with antiphospholipid antibody-related stroke | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-91739-w
5. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/ ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001415
6. Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-020-59990-5
7. Reviews & Analysis — www.nature.com — https://www.nature.com/nrrheum/reviews-and-analysis?searchType=journalSearch&sort=PubDate&year=2024&page=3
8. Direct Oral Anticoagulants vs Vitamin K Antagonists in ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2022.10.008
9. Assessment of Cardiac Structure and Left Atrial ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/01.STR.0000154858.27353.df
10. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis | Nature Reviews Rheumatology — www.nature.com — https://www.nature.com/articles/s41584-023-00958-w
11. Increased Risk for Heart Valve Disease Associated With ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circulationaha.111.028522
12. Design and Implementation of an Automated Interpretation Algorithm for Lupus Anticoagulant Functional Testing — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/ijlh.70153
13. Antiphospholipid antibody testing and standardization — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/ijlh.12234
14. Triage and care for women with symptoms or diagnosis of pregnancy loss between 14 + 0 and 21 + 6 weeks' gestation - Fox - 2026 - International Journal of Gynecology & Obstetrics - Wiley Online Library — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.70621
15. British Journal of Haematology — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/bjh.19635
16. Guidelines on the investigation and management ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19635
17. Antiphospholipid Syndrome: An Antibody‐Mediated Disease ... — acrjournals.onlinelibrary.wiley.com — https://acrjournals.onlinelibrary.wiley.com/doi/full/10.1002/art.43258
18. ISPRM 2020 : The Journal of the International Society ... — journals.lww.com — https://journals.lww.com/jisprm/fulltext/2020/03001/isprm_2020__abstracts_of_scientific_papers_and.1.aspx
19. a conversation about thrombocytopenia and ... — journals.lww.com — https://journals.lww.com/co-rheumatology/_layouts/15/oaks.journals/downloadpdf.aspx?an=00002281-201905000-00004
20. 22nd PANLAR Congress: Miami, FL, August 12-15 2020 — journals.lww.com — https://journals.lww.com/jclinrheum/fulltext/2020/04001/22nd_panlar_congress__miami,_fl,_august_12_15_2020.1.aspx
21. Management of Antiphospholipid Syndrome — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7696303
22. Warfarin and heparin monitoring in antiphospholipid syndrome — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11665698
23. Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events? — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5045335
24. Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8368436

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.